HAGEMANN ROBERT 4

What Happened
Robert Hagemann, a director of Zimmer Biomet Holdings (ZBH), received an award of 308.711 phantom stock units on 2026-03-31. The units were granted at $0.00 (no upfront purchase price) and are derivative phantom units (conversion/exercise 1-for-1). The filing shows the units will be settled in cash over time rather than resulting in immediate share ownership.

Key Details

• Transaction date and type: 2026-03-31 — Grant/Award of 308.711 phantom stock units (Derivative, code A).
• Price: $0.00 per unit (no cash paid on grant).
• Total reported value on form: $0 (units are deferred/derivative; cash value depends on future stock price).
• Shares owned after transaction: not disclosed in this filing.
• Notable footnotes:
  • Units accrued under the Zimmer Biomet Deferred Compensation Plan for Non‑Employee Directors (F1).
  • Conversion/exercise is 1-for-1 (each unit corresponds to one share equivalent) (F2).
  • Units to be settled in cash in five annual installments beginning within 60 days after the year in which the director leaves service (F3).
  • Includes 87.178 phantom units accrued on 2026-01-30 via the plan’s dividend reinvestment provision (F4).
• Filing timeliness: Form filed 2026-04-02 for a 2026-03-31 transaction; no late filing flag indicated.

Context
Phantom stock units are a form of deferred compensation for non‑employee directors and do not represent immediate stock transfers. Here, the units will be cash‑settled in installments after Hagemann leaves the board, so this grant is primarily compensation rather than an indication of an insider buying or selling shares.